Last Update 09 Mar 26

CLBT: 2026 Revenue Guidance Will Support Earnings Power Despite P/E Recalibration

Analysts have trimmed their price targets on Cellebrite DI by $2, reflecting updated views on the stock's future P/E multiple and risk profile, while keeping key growth and profitability assumptions largely unchanged.

Analyst Commentary

Recent research updates suggest that analysts are adjusting their views on Cellebrite DI more around valuation mechanics than around its underlying business assumptions. The $2 trim in price targets is being framed as a recalibration of the appropriate P/E multiple and risk profile rather than a reset of growth or profitability expectations.

Bullish Takeaways

Bullish analysts highlight that core growth and profitability assumptions are largely intact. They view this as support for maintaining a constructive stance on the long term story despite the lower price targets.
They view the updated P/E multiple as an attempt to align the stock with a risk profile they consider more realistic rather than a signal that the underlying execution outlook has materially weakened.
Some bullish analysts point to the fact that target cuts are modest at $2. They interpret this as a fine tuning of valuation models instead of a broad shift in view on Cellebrite DI's ability to grow into its earnings base.
There is an ongoing focus among bullish analysts on the company’s potential to convert its existing assumptions around profitability into actual earnings delivery. They believe this can still support a premium to certain peers over time.

Bearish Takeaways

Bearish analysts see the reduced P/E multiple as a sign that the market may need a higher margin of safety given Cellebrite DI's perceived risk profile. They suggest this could cap upside if execution does not clearly outpace current assumptions.
They flag that, while growth and profitability assumptions are unchanged, any misstep versus those expectations could now be met with a less forgiving valuation framework.
Some bearish analysts focus on the risk that current targets still embed optimistic execution on both growth and margin delivery. They argue this leaves limited room for error relative to the updated price targets.
There is concern among bearish analysts that the revised valuation may still not fully reflect potential volatility around the company’s risk profile, especially if investor sentiment turns more cautious on names with similar P/E assumptions.

What's in the News

Cellebrite DI issued earnings guidance for the first quarter of 2026, with expected revenue in a range of $126 million to $128 million (company guidance).
The company also provided full year 2026 revenue guidance, targeting a range of $565 million to $571 million (company guidance).
These revenue ranges give investors specific benchmarks to track as quarterly results are released through 2026 (company guidance).

Valuation Changes

Fair Value: Model fair value remains unchanged at $21.67. This indicates no adjustment to the core valuation output.
Discount Rate: The discount rate has risen slightly from 10.47% to 10.60%, signalling a small increase in the required return used in the model.
Revenue Growth: The revenue growth assumption is effectively unchanged at 17.51%, with only a minimal numerical adjustment in the updated model.
Profit Margin: The net profit margin assumption remains stable at 17.19%, reflecting no practical change in projected profitability.
Future P/E: The future P/E multiple has risen slightly from 59.68x to 63.87x, indicating a higher valuation multiple applied to the same earnings base.

0 views

Key Takeaways

Accelerating digital crime and security demands are boosting adoption of Cellebrite's forensic SaaS platforms, driving strong subscription growth and deeper customer relationships.
Emphasis on privacy compliance, AI innovation, and recurring revenue is expanding market opportunities, supporting premium pricing, and improving margins and valuation prospects.
Heavy reliance on US federal contracts, regulatory headwinds, and competition-driven R&D needs threaten Cellebrite's growth, margins, and diversification, increasing risks of revenue volatility and market erosion.

Catalysts

About Cellebrite DI

Develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.What are the underlying business or industry changes driving this perspective?

The accelerating shift by law enforcement and intelligence agencies toward more advanced digital investigation platforms, driven by surging digitalization, larger data volumes, and increasing crime sophistication, is fueling rapid adoption of Cellebrite's cloud/SaaS solutions and digital forensics platforms (Inseyets, Guardian, Pathfinder), which is set to drive continued double-digit subscription revenue and ARR growth over the coming years.
Heightened global security focus, including rising budgets for defense and intelligence (especially in Europe amid geopolitical tension and in the US as new federal allocations are released), is expected to result in a sharp resurgence of demand and larger contract values in 2026, supporting a return to higher top-line growth and increased customer stickiness.
Strengthening privacy and data protection regulations are paradoxically expanding the need for Cellebrite's forensically-sound, compliant data access and investigation tools, reinforcing the company's competitive positioning, supporting premium pricing, and helping sustain high gross margins.
Ongoing innovation in AI-powered analytics and automation, as well as the integration of strategic acquisitions like Corellium (expanding access to ARM device forensics and new private sector verticals), is set to increase Cellebrite's total addressable market (TAM), improve product differentiation, and support both revenue and margin expansion over the long term.
The continued transition to a recurring, subscription-based revenue model-with over 90% of revenues now from subscriptions and growing SaaS/cloud penetration-improves revenue visibility, predictability, and operating leverage, which is already translating into higher EBITDA and free cash flow margins and is likely underappreciated in current valuations.

Cellebrite DI Earnings and Revenue Growth

Cellebrite DI Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Cellebrite DI's revenue will grow by 15.4% annually over the next 3 years.
Analysts assume that profit margins will increase from -34.6% today to 19.2% in 3 years time.
Analysts expect earnings to reach $128.8 million (and earnings per share of $0.44) by about September 2028, up from $-150.9 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $146.7 million in earnings, and the most bearish expecting $105.3 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 71.0x on those 2028 earnings, up from -26.7x today. This future PE is greater than the current PE for the US Software industry at 36.6x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 10.67%, as per the Simply Wall St company report.

Cellebrite DI Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Cellebrite's over-reliance on U.S. federal government contracts introduces significant revenue instability; ongoing delays and constrained visibility into federal spending cycles, combined with procurement and budget bottlenecks, led management to lower guidance and signal that near-term ARR growth is materially impacted-with the company explicitly noting that the federal segment's slow recovery subtracts approximately 4 percentage points from total ARR growth for 2025, directly limiting revenue and earnings growth.
Heightened competition and rapid advances in mobile OS security (notably Apple and Google anti-forensics measures) continue to necessitate escalating R&D investment to sustain Cellebrite's lawful access capabilities; if device manufacturers and privacy advocates successfully harden devices or limit data accessibility faster than Cellebrite can innovate, the long-term relevance and pricing power of Cellebrite's solutions may erode, compressing margins and jeopardizing market share.
Increasing global privacy regulations and tightening data protection laws (such as GDPR, CCPA, and new standards emerging in Europe and other regions) could place greater restrictions on digital evidence extraction, potentially shrinking Cellebrite's addressable market, adding compliance costs, and placing downward pressure on future revenue growth-especially as public and political resistance to digital surveillance grows.
Although international and private sector expansion are highlighted as growth drivers (with recent momentum in EMEA, Latin America, and early Corellium sales), the company's commentary indicates these segments remain a small portion of overall revenue-leaving Cellebrite exposed to geographic and customer concentration risk that could limit earnings diversification and increase volatility during sector-specific demand shocks.
Ambitious investments in AI-driven innovation and acquisitions (such as Corellium) carry execution and integration risks; failure to deliver anticipated operational efficiencies, premium product capabilities, or market expansion could result in elevated costs without corresponding revenue or gross margin improvement, constraining net income and potentially disappointing investors counting on high-margin, innovation-led growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $22.571 for Cellebrite DI based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $28.0, and the most bearish reporting a price target of just $18.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $671.4 million, earnings will come to $128.8 million, and it would be trading on a PE ratio of 71.0x, assuming you use a discount rate of 10.7%.
Given the current share price of $16.51, the analyst price target of $22.57 is 26.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Cellebrite DI?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Cloud SaaS Solutions Will Drive Digital Forensics Adoption